AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy. We report the characterization of AC220, a second-generation FLT3 inhibitor, a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zarrinkar, Patrick P., Gunawardane, Ruwanthi N., Cramer, Merryl D., Gardner, Michael F., Brigham, Daniel, Belli, Barbara, Karaman, Mazen W., Pratz, Keith W., Pallares, Gabriel, Chao, Qi, Sprankle, Kelly G., Patel, Hitesh K., Levis, Mark, Armstrong, Robert C., James, Joyce, Bhagwat, Shripad S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2009
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756206/
https://ncbi.nlm.nih.gov/pubmed/19654408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados